Report
Pathos AI announces $237 million Series E at $3 billion valuation
SiliconANGLE reports Bristol Myers Squibb led the round, which Pathos plans to put toward its cancer-drug programs.
TLDR
SiliconANGLE reports Pathos AI announced a $237 million Series E at a $3 billion valuation, led by Bristol Myers Squibb. Pathos plans to use the funding for its cancer-drug pipeline, with JSKN016 its stated priority. Techmeme, citing Axios, says Pathos was valued at $1.6 billion in May 2025.
Combined views
4.5K
2 Sources, first seen ago